Holen Sie sich die Stockscreener-App
10.25
0.93%
0.0788
Schlusskurs vom Vortag:
$10.17
Offen:
$10.342
24-Stunden-Volumen:
5.80M
Relative Volume:
1.17
Marktkapitalisierung:
$2.60B
Einnahmen:
$885.72M
Nettoeinkommen (Verlust:
$-457.98M
KGV:
-5.7691
EPS:
-1.7765
Netto-Cashflow:
$293.05M
1W Leistung:
+2.65%
1M Leistung:
+22.06%
6M Leistung:
+29.61%
1J Leistung:
+17.18%
1-Tages-Spanne:
$10.00
$10.42
1-Wochen-Bereich:
$9.515
$10.42
52-Wochen-Spanne:
$6.00
$10.94
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
10.24 | 2.58B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
16.98 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.845 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.60 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.03 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
558.72 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Fortgesetzt | Evercore ISI | Outperform |
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating - marketscreener.com
BCRXBiocryst Pharmaceuticals Inc Volatility & Greeks - Finviz
BioCryst lures 9 new hires with stock awards tied to $9.65 shares - Stock Titan
How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story - Sahm
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $16 to $32 - Moomoo
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
BioCryst Pharmaceuticals Inc (BCRX) Stock Up 4.6% and Still Unde - GuruFocus
How (BCRX) Movements Inform Risk Allocation Models - Stock Traders Daily
BCRX Maintained by Cantor Fitzgerald -- Price Target Raised to $29 - GuruFocus
BioCryst to Close Birmingham Research Facility by End of 2026 - WBMA
BioCryst Pharmaceuticals (BCRX) Surges 4.8% as Bullish Volume Lifts Stock Toward Key ResistanceExtension Target - dars.gov.et
BCRX Maintained by HC Wainwright & Co. -- Price Target Stays at $32 - GuruFocus
BioCryst Pharmaceuticals Price Target Maintained With a $32.00/Share by HC Wainwright & Co. - Moomoo
BioCryst winds down internal discovery as it pivots to external innovation - The Pharma Letter
Jefferies raises BioCryst stock price target on R&D shift By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
BioCryst Pharmaceuticals (BCRX) Shifts Focus to External Innovat - GuruFocus
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
BioCryst (BCRX) to Halt Internal Research Programs in Strategic Shift - GuruFocus
BioCryst Refocuses on External Innovation, Winds Down Internal R&D and Closes Birmingham Facility to Accelerate Rare Disease Pipeline Growth – Minichart - Minichart
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs - marketscreener.com
BioCryst to close Alabama research facility, cut costs By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
BioCryst to close Alabama research facility, cut costs - Investing.com
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub - Stock Titan
BioCryst shuts Birmingham lab, cuts 2026 spending outlook - Stock Titan
BCRX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
Price to earnings forward of BioCryst Pharmaceuticals, Inc. – BX:BO1 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – BX:BO1 - TradingView
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Price to sales forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to sales forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Price to book forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
Enterprise value to EBITDA forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Enterprise value to EBIT forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (DUS:BO1) - TradingView
Fierce Biotech Layoff Tracker 2026: BioCryst ends internal programs; Biogen sheds Apellis R&D roles - Fierce Biotech
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:BCRX) - TradingView
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (SWB:BO1) - TradingView
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level - Yahoo Finance
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 By Investing.com - Investing.com Australia
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 - Investing.com
BioCryst Pharmaceuticals options trading jumps to 13,522 - Investing.com
BioCryst (BCRX) Is Up 11.7% After New HAE Data Spotlight ORLADEYO And Navenibart Potential - Sahm
BioCryst Pharmaceuticals options trading jumps to 13,522 By Investing.com - Investing.com Australia
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals Inc (BCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trading Systems Reacting to (BCRX) Volatility - Stock Traders Daily
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):